{"denomUnitsSelected":"Participants","description":"Tumor tissue biomarkers correlated with outcome to pembrolizumab or cetuximab, such as PD-L1 expression, EGFR expression, p16 status, and immunophenotyping","reportingStatus":"NOT_POSTED","timeFrame":"Tumor specimens (archival or new specimen) should be obtained within 42 days of screening","title":"Correlative Analyses","type":"SECONDARY"}